Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Enterprise Value (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Enterprise Value for 12 consecutive years, with -$189.2 million as the latest value for Q1 2026.

  • For Q1 2026, Enterprise Value fell 743.39% year-over-year to -$189.2 million; the TTM value through Mar 2026 reached -$189.2 million, down 743.39%, while the annual FY2025 figure was -$213.2 million, N/A changed from the prior year.
  • Enterprise Value hit -$189.2 million in Q1 2026 for Crescent Biopharma, up from -$213.2 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$14.4 million in Q3 2024 and bottomed at -$213.2 million in Q4 2025.
  • Average Enterprise Value over 5 years is -$71.8 million, with a median of -$51.6 million recorded in 2022.
  • Year-over-year, Enterprise Value skyrocketed 70.85% in 2024 and then tumbled 825.45% in 2025.
  • Crescent Biopharma's Enterprise Value stood at -$47.9 million in 2022, then increased by 12.7% to -$41.8 million in 2023, then surged by 65.54% to -$14.4 million in 2024, then tumbled by 1380.5% to -$213.2 million in 2025, then increased by 11.27% to -$189.2 million in 2026.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$189.2 million, -$213.2 million, and -$133.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.